REFERENCES
1. Ginsburg, O. et al. The global burden of women’s cancers: a grand challenge in global health. Lancet 389 , 847–860 (2017).
2. Ferlay, J. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase. No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. 11 , http://globocan.iarc.f (2013).
3. Farmer, P. et al. Expansion of cancer care and control in countries of low and middle income: A call to action. The Lancet376 , 1186–1193 (2010).
4. Tsu, V. & Jerónimo, J. Saving the World’s Women from Cervical Cancer. N. Engl. J. Med. 374 , 2509–2511 (2016).
5. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 68 , (2018).
6. UNDP. What is Human Development? UNDP Hum. Dev. Reports(2017).
7. Wittet, S. & Tsu, V. Cervical cancer prevention and the Millennium Development Goals. Bull. World Health Organ. 86 , 488–490 (2008).
8. WHO. Global action plan for the prevention and control of noncommunicable diseases 2013-2020. World Heal. Organ. 102 (2013). doi:978 92 4 1506236
9. WHO. Global strategy to accelerate the elimination of cervical cancer as a public health problem and its associated goals and targets for the period 2020 – 2030 . United Nations General Assembly2 , (2020).
10. Gaffikin, L., Blumenthal, P. D., McGrath, J. & Chirenje, Z. M. Visual inspection with acetic acid for cervical-cancer screening: Test qualities in a primary-care setting. Lancet 353 , 869–873 (1999).
11. Yimer, N. B. et al. Cervical cancer screening uptake in Sub-Saharan Africa: a systematic review and meta-analysis. Public Health 195 , (2021).
12. Kitchener, H. C., Castle, P. E. & Cox, J. T. Chapter 7: Achievements and limitations of cervical cytology screening.Vaccine 24 , (2006).
13. Peto, J., Gilham, C., Fletcher, O. & Matthews, F. E. The cervical cancer epidemic that screening has prevented in the UK. Lancet (London, England) 364 , 249–56 (2004).
14. Maza, M. et al. Cervical Precancer Treatment in Low- and Middle-Income Countries: A Technology Overview. J Glob Oncol(2016). doi:10.1200/JGO.2016.003731
15. Gonzalez, C. D. I. et al. Recurrence of dysplasia after loop electrosurgical excision procedures with long-term follow-up. Am. J. Obstet. Gynecol. 184 , 315–321 (2001).
16. Soutter, W. P., Sasieni, P. & Panoskaltsis, T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int. J. Cancer 118 , 2048–55 (2006).
17. Santesso, N. et al. Systematic reviews and meta-analyses of benefits and harms of cryotherapy, LEEP, and cold knife conization to treat cervical intraepithelial neoplasia. International Journal of Gynecology and Obstetrics 132 , 266–271 (2016).
18. Kyrgiou, M. et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: Systematic review and meta-analysis. Lancet 367 , 489–498 (2006).
19. Arbyn, M. et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 337 , a1284 (2008).
20. Kyrgiou, M. et al. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. Bmj 349 , g6192–g6192 (2014).
21. Fruchter, R. G. et al. Multiple recurrences of cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Obstet. Gynecol. 87 , 338–44 (1996).
22. Maiman, M. et al. Recurrent cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women.Obstet. Gynecol. 82 , 170–174 (1993).
23. Paramsothy, P. et al. Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy. J. Acquir. Immune Defic. Syndr. 35 , 484–491 (2004).
24. Petry, K. U. et al. Cellular immunodeficiency enhances the progression of human papillomavirus‐associated cervical lesions.Int. J. Cancer 57 , 836–840 (1994).
25. Heard, I., Palefsky, J. M. & Kazatchkine, M. D. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antiviral Therapy 9 , 13–22 (2004).
26. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J. Natl. Cancer Inst. 92 , 1823–30 (2000).
27. Heard, I. et al. High rate of recurrence of cervical intraepithelial neoplasia after surgery in HIV-positive women. J. Acquir. Immune Defic. Syndr. 39 , 412–8 (2005).
28. Tainio, K. et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. Bmj k499 (2018). doi:10.1136/bmj.k499
29. Jalil, A., Wert, J., Farooq, A. & Ahmad, S. Overcoming drug resistance in cervical cancer: Chemosensitizing agents and targeted therapies. in Overcoming Drug Resistance in Gynecologic Cancers195–205 (Elsevier Inc., 2021). doi:10.1016/b978-0-12-824299-5.00010-1
30. Zhu, H. et al. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Design, Development and Therapy10 , (2016).
31. Song, W., Jiang, R. & Zhao, C. M. Role of integrin-linked kinase in multi-drug resistance of human gastric carcinoma SGC7901/DDP cells.Asian Pacific J. Cancer Prev. 13 , (2012).
32. Ali, A. Y. et al. Molecular determinants of ovarian cancer chemoresistance: New insights into an old conundrum. Ann. N. Y. Acad. Sci. 1271 , (2012).
33. Amable, L. Cisplatin resistance and opportunities for precision medicine. Pharmacological Research 106 , (2016).
34. Siddik, Z. H. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22 , (2003).
35. Sengayi-Muchengeti, M. et al. Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index: A population-based registry study. Int. J. Cancer147 , (2020).
36. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA. Cancer J. Clin. 71 , (2021).
37. Chinombe, N., Sebata, N. L., Ruhanya, V. & Matarira, H. T. Human papillomavirus genotypes in cervical cancer and vaccination challenges in Zimbabwe. Infect. Agent. Cancer 9 , 16 (2014).
38. Mahantshetty, U. et al. Incidence, Treatment and Outcomes of Cervical Cancer in Low- and Middle-income Countries. Clin. Oncol.33 , (2021).
39. Sreekanth, C. N., Bava, S. V., Sreekumar, E. & Anto, R. J. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer.Oncogene 30 , 3139–3152 (2011).
40. Roy, M. & Mukherjee, S. Reversal of resistance towards cisplatin by curcumin in cervical cancer cells. Asian Pacific J. Cancer Prev.15 , 1403–1410 (2014).
41. UNAIDS. Epidemiological Fact Sheet on HIV and AIDS - Zimbabwe. (2013).
42. Goodman, A. HPV testing as a screen for cervical cancer. Bmj350 , h2372–h2372 (2015).
43. Muñoz, N. & Bosch, F. X. The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer.Bull. Pan Am. Health Organ. 30 , 362–377 (1996).
44. Dunne, E. F. et al. Prevalence of HPV infection among females in the United States. JAMA 297 , 813–819 (2007).
45. Stern, P. L. et al. Therapy of human papillomavirus-related disease. Vaccine 30 , (2012).
46. Desravines, N., Miele, K., Carlson, R., Chibwesha, C. & Rahangdale, L. Topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) 2–3: A narrative review. Gynecologic Oncology Reports (2020). doi:10.1016/j.gore.2020.100608
47. Grimm, C. et al. Treatment of cervical intraepithelial neoplasia with topical imiquimod: A randomized controlled trial.Obs. Gynecol 120 , 152–159 (2012).
48. Pachman, D. R. et al. Randomized clinical trial of imiquimod: An adjunct to treating cervical dysplasia. Am. J. Obstet. Gynecol. 206 , (2012).
49. Lin, C.-T. et al. Topical imiquimod treatment for human papillomavirus infection in patients with and without cervical/vaginal intraepithelial neoplasia. Taiwan. J. Obstet. Gynecol.51 , 533–8 (2012).
50. Maiman, M. et al. Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: a randomized trial. Obstet. Gynecol. 94 , 954–61 (1999).
51. Rahangdale, L. et al. Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: A randomized controlled trial.Am. J. Obstet. Gynecol. 210 , (2014).
52. Van Pachterbeke, C. et al. Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol. Oncol. 115 , 69–74 (2009).
53. Hampson, L. et al. A Single-Arm, Proof-Of-Concept Trial of Lopimune (Lopinavir/Ritonavir) as a Treatment for HPV-Related Pre-Invasive Cervical Disease. PLoS One 11 , (2016).
54. Batman, G. et al. Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells. Antivir. Ther. 16 , 515–525 (2011).
55. Lahiri, C. D. et al. Oral lopinavir use and human papillomavirus infection in HIV-positive women. Journal of Acquired Immune Deficiency Syndromes 70 , e63–e66 (2015).
56. Niwa, K. et al. Topical vidarabine or 5-fluorouracil treatment against persistent HPV in genital (pre)cancerous lesions.Oncol. Rep. (2003). doi:10.3892/or.10.5.1437
57. Okamoto, A. et al. Combination therapy with podophyllin and vidarabine for human papillomavirus positive cervical intraepithelial neoplasia. Oncol. Rep. (1999). doi:10.3892/or.6.2.269
58. Khanna, N. et al. Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol. Oncol. (2007). doi:10.1016/j.ygyno.2007.08.074
59. Suh-Burgmann, E., Sivret, J., Duska, L. R., Del Carmen, M. & Seiden, M. V. Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia - A pilot study. Gynecol. Obstet. Invest. (2003). doi:10.1159/000068953
60. Ahn, W. S. et al. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur. J. Cancer Prev. (2003). doi:10.1097/00008469-200310000-00007
61. Shukla, S. et al. Elimination of high-risk human papillomavirus type HPV16 infection by ‘Praneem’ polyherbal tablet in women with early cervical intraepithelial lesions. J. Cancer Res. Clin. Oncol. (2009). doi:10.1007/s00432-009-0617-1
62. Valencia, M. H., Pacheco, A. C., Quijano, T. H., Girón, A. V. & López, C. V. Clinical response to glycyrrhizinic acid in genital infection due to human papillomavirus and low-grade squamous intraepithelial lesion. Clin. Pract. (2011). doi:10.4081/cp.2011.e93
63. Cohen, L. Influence of pH vaginal discharges. Obstet. Gynecol. Surv. (1970). doi:10.1097/00006254-197008000-00026
64. Kelly, K. G. Tests on Vaginal Discharge. Clin. Methods Hist. Phys. Lab. Exam. (1990).
65. Redondo-Lopez, V., Cook, R. L. & Sobel, J. D. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev. Infect. Dis. (1990). doi:10.1093/clinids/12.5.856
66. Correa, C. H. M., Mattos, A. L. G. & Ferrari, A. N. In situ variation of cervical mucus pH during exposure to atmospheric air.Brazilian J. Med. Biol. Res. (2001). doi:10.1590/S0100-879X2001000600011
67. Layek, B. & Das, S. Chitosan-based nanomaterials in drug delivery applications. in Biopolymer-Based Nanomaterials in Drug Delivery and Biomedical Applications (2021). doi:10.1016/b978-0-12-820874-8.00001-4
68. Krishna, S., Ashok, V. & Chatterjee, A. A Review on Vaginal Drug Delivery Systems. International Journal of Biology, Pharmacy and applied Sciences 1 , 152–167 (2012).
69. Bilensoy, E., Rouf, M. A., Vural, I., Şen, M. & Hincal, A. A. Mucoadhesive, thermosensitive, prolonged-release vaginal gel for clotrimazole: β-cyclodextrin complex. AAPS PharmSciTech7 , (2006).
70. Deshpande, T., Shinde, R. & Pawar, Y. Mucoadhesive Drug Delivery System - Vaginal. in Drug Delivery Systems - A Review (ed. Gothoskar, A. V) 160–181 (e-book, 2012).
71. David Woolfson, A. Intravaginal Drug Delivery Technologies. in (2002). doi:10.1201/9780203910337.pt8
72. Deshpande, A. A., Rhodes, C. T. & Danish, M. Intravaginal drug delivery. Drug Dev. Ind. Pharm. 18 , (1992).
73. Lacey, C. J. N. Therapy for genital human papillomavirus-related disease. Journal of Clinical Virology 32 , (2005).
74. das Neves, J. & Bahia, M. F. Gels as vaginal drug delivery systems.International Journal of Pharmaceutics 318 , (2006).
75. Hussain, A. & Ahsan, F. The vagina as a route for systemic drug delivery. Journal of Controlled Release 103 , (2005).
76. Hardy, E., Jiménez, A. L., De Pádua, K. S. & Zaneveld, L. J. D. Women’s preferences for vaginal antimicrobial contraceptives III: Choice of a formulation, applicator, and packaging. Contraception58 , (1998).
77. Vigani, B. et al. Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes. Pharmaceutics 12 , (2020).
78. Pall, A., Mahajan, B. B., Puri, K. P. S. & Gupta, R. R. Therapeutic Evaluation of Intralesional 5% 5-Fluorouracil in Condyloma Acuminata.J. Dermatol. 31 , (2004).
79. Longley, D. B., Harkin, D. P. & Johnston, P. G. 5-Fluorouracil: Mechanisms of action and clinical strategies. Nature Reviews Cancer (2003). doi:10.1038/nrc1074
80. Longley, D. B., Harkin, D. P. & Johnston, P. G. 5-Fluorouracil: Mechanisms of action and clinical strategies. Nature Reviews Cancer 3 , (2003).
81. Sommer, H. & Santi, D. V. Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2′-deoxyuridylate and methylenetetrahydrofolate.Biochem. Biophys. Res. Commun. (1974). doi:10.1016/0006-291X(74)90601-9
82. Santi, D. V., McHenry, C. S. & Sommer, H. Mechanism of Interaction of Thymidylate Synthetase with 5-Fluorodeoxyuridylate.Biochemistry (1974). doi:10.1021/bi00700a012
83. Stanley, M. Chapter 17: Genital human papillomavirus infections–current and prospective therapies. J. Natl. Cancer Inst. Monogr. 6 , 117–124 (2003).
84. van de Nieuwenhof, H. P., van der Avoort, I. A. M. & de Hullu, J. A. Review of squamous premalignant vulvar lesions. Critical Reviews in Oncology/Hematology 68 , 131–156 (2008).
85. Krebs, H. B. Prophylactic topical 5-fluorouracil following treatment of human papillomavirus-associated lesions of the vulva and vagina.Obstet. Gynecol. 68 , (1986).
86. Krebs, H. B. & Helmkamp, B. F. Chronic ulcerations following topical therapy with 5-fluorouracil for vaginal human papillomavirus- associated lesions. Obstet. Gynecol. 78 , (1991).
87. Edwards, L. et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch. Dermatol. 134 , (1998).
88. Garland, S. M., Waddell, R., Mindel, A., Denham, M. & McCloskey, J. C. An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. Int. J. STD AIDS 17 , (2006).
89. Stockfleth, E. et al. Topical Polyphenon® E in the treatment of external genital and perianal warts: A randomized controlled trial.Br. J. Dermatol. 158 , (2008).
90. Tatti, S. et al. Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: A randomized controlled trial. Obstet. Gynecol. 111 , (2008).
91. Pride, G. L. & Chuprevich, T. W. Topical 5-fluorouracil treatment of transformation zone intraepithelial neoplasia of cervix and Vagina.Obstet. Gynecol. (1982).
92. Barten, G. [Local treatment of cervical intraepithelial neoplasia with a 5 percent fluorouracil ointment]. Zentralbl. Gynakol.(1987).
93. Sidhu, H. K. et al. A randomised controlled trial evaluating a novel cytotoxic drug delivery system for the treatment of cervical intraepithelial neoplasia. BJOG An Int. J. Obstet. Gynaecol.(1997). doi:10.1111/j.1471-0528.1997.tb11034.x
94. Bilensoy, E., Çırpanlı, Y., Şen, M., Doğan, A. L. & Çalış, S. Thermosensitive mucoadhesive gel formulation loaded with 5-Fu: Cyclodextrin complex for HPV-induced cervical cancer. J. Incl. Phenom. Macrocycl. Chem. 57 , 363–370 (2007).
95. Lea, A. P. & Bryson, H. M. Cidofovir. Drugs 52 , 225–230 (1996).
96. De Schutter, T., Andrei, G., Topalis, D., Naesens, L. & Snoeck, R. Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage. BMC Med. Genomics (2013). doi:10.1186/1755-8794-6-18
97. Andrei, G., Snoeck, R., Schols, D. & De Clercq, E. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells.Oncol. Res. (2000). doi:10.3727/096504001108747855
98. Bossens, M. et al. Safety and tolerance of cidofovir as a 2% gel for local application in high-grade cervical intraepithelial neoplasia: A phase 1 investigation. Int. J. Clin. Pharmacol. Ther. (2018). doi:10.5414/CP203126
99. Snoeck, R., Noel, J. C., Muller, C., De Clercq, E. & Bossens, M. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J. Med. Virol. 60 , (2000).
100. Hampson, L., Kitchener, H. C. & Hampson, I. N. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.Antivir. Ther. 11 , 813–825 (2006).
101. Kwara, A. et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin. Infect. Dis.46 , 719–25 (2008).
102. Zehbe, I. et al. Lopinavir shows greater specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus-related lesions. Antiviral Res. 91 , 161–166 (2011).
103. Pasley, M. V., Martinez, M., Hermes, A., D’Amico, R. & Nilius, A. Safety and efficacy of lopinavir/ritonavir during pregnancy: A systematic review. AIDS Reviews 15 , (2013).
104. Phillips, R. M., Hendriks, H. R. & Peters, G. J. EO9 (Apaziquone): From the clinic to the laboratory and back again. British Journal of Pharmacology 168 , 11–18 (2013).
105. Phillips, R. M., Hendriks, H. R., Sweeney, J. B., Reddy, G. & Peters, G. J. Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer.Expert Opin. Drug Metab. Toxicol. 13 , 783–791 (2017).
106. Phillips, R. M. Prospects for bioreductive drug development.Expert Opin. Investig. Drugs 7 , 905–928 (1998).
107. Puri, R. et al. Phase I/II Pilot Study of Intravesical Apaziquone (EO9) for Superficial Bladder Cancer. J. Urol. (2006). doi:10.1016/j.juro.2006.06.047
108. van der Heijden, A. G. et al. Phase II Marker Lesion Study With Intravesical Instillation of Apaziquone for Superficial Bladder Cancer: Toxicity and Marker Response. J. Urol. (2006). doi:10.1016/j.juro.2006.06.007
109. Jain, A. et al. Response of Multiple Recurrent TaT1 Bladder Cancer to Intravesical Apaziquone (EO9): Comparative Analysis of Tumor Recurrence Rates. Urology 73 , (2009).
110. Hendricksen, K. et al. Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J. Urol. 27 , (2009).
111. Ma, Y. et al. NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix. BMC Cancer 14 , 414 (2014).